Table A4.
Univariate Analysis of Risk Factors Associated With Development of Secondary Breast Cancer in Female Patients With HL (n = 35)
| Factor | Breast Cancer (n = 6) | No Breast Cancer (n = 29) | P* |
|---|---|---|---|
| Age at HL diagnosis, years | |||
| < 11 | 0 | 9 | |
| ≥ 11 | 6 | 20 | .31 |
| Mean | 13.8 | 11.8 | |
| SD | 1.4 | 3.1 | |
| Range | 11.5-15.8 | 4.3-15 | .13 |
| Stage | |||
| I/II | 3 | 14 | 1.00 |
| III/IV | 3 | 15 | |
| Chemotherapy | |||
| MOPP | 2 | 12 | 1.00 |
| ABVD/MOPP | 4 | 17 | |
| Mean mantle radiation dose, Gy | 23.3 | 18.5 | .29 |
| Range | 15-25.6 | 0-43 | |
| Pelvic radiotherapy | |||
| Yes | 1 | 8 | 1.00 |
| No | 5 | 21 | |
| Mean follow-up time, years | 22.9 | 19.7 | .39 |
| SD | 3.3 | 6.8 | |
| Range | 17.2-30 | 2-32.9 | |
| Mean age at last contact | 36.7 | 31.4 | .14 |
| SD | 2.7 | 6.6 | |
| Range | 30.6-41.8 | 14.5-44.1 |
Abbreviations: HL, Hodgkin's lymphoma; SD, standard deviation; MOPP mechlorethamine, vincristine, procarbazine, prednisone; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine.